NCT07344220
Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate
Enrolling by Invitation
PHASE2Ages 18+InterventionalTreatmentHoag Memorial Hospital PresbyterianInvestigator-initiated
~39 participants
Updated 2026-01-15 on ClinicalTrials.gov
What's tested:DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recommended Phase 2 Dose (RP2D)
Measured over Up to 28 days of last patient dosed during the escalation phase
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Carlos Becerra, MD · PRINCIPAL_INVESTIGATOR · Hoag Memorial Hospital Presbyterian
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Recommended Phase 2 Dose (RP2D)Up to 28 days of last patient dosed during the escalation phase
To determine the RP2D
- Incidence of Dose Limiting Toxicities (DLTs)Up to 28 days
Dose limiting toxicities refer to toxicities experienced during the first 28 days of DZ-002 treatment that have been judged to be clinically significant and related to study treatment.